Efficient Project Management for a Late-Stage Parkinson’s Disease Study 

1 minute read

Published: January 6th, 2026

Phastar partnered with a biotechnology sponsor to manage statistical and data management activities for a late-stage clinical study in Parkinson’s disease. The project involved distributed teams, complex neurosurgical procedures, and questionnaire-driven endpoints—all under tight budget oversight. 

Key Challenges: 

  • Global team coordination across multiple time zones 
  • Limited internal statistical and data management expertise 
  • Complex CRF design for neurosurgical injections and questionnaire-based endpoints 
  • Need for strict oversight and cost control 

Our Approach: 

  • Scheduled cross-time-zone meetings to maximize participation and maintain momentum 
  • Provided clear, proactive explanations to support sponsor understanding at each stage 
  • Conducted detailed multidisciplinary reviews of complex CRF pages 
  • Ensured strict adherence to the project timeline to minimize rework and control budget impact 

Outcome: 

The study progressed smoothly, earning strong praise from all stakeholders. The sponsor commended Phastar’s professionalism, attention to detail, and proactive approach, noting significant improvements in collaboration, clarity, and project efficiency. 

Complete the form below to read the full case study

Related articles

Turning Legacy Complexity into Submission-Ready Confidence

Turning Legacy Complexity into Submission-Ready Confidence

November 24th, 2025 1 minute read

Discover how Phastar converted 16 legacy studies into SDTM and delivered a robust Integrated Summary of Safety (ISS) ...

Delivering a Complex Integrated Summary of Effectiveness: Efficient Pooling and Advanced Analysis Across Four Multiple Sclerosis Spasticity Studies 

Delivering a Complex Integrated Summary of Effectiveness: Efficient Pooling and Advanced Analysis Across Four Multiple Sclerosis Spasticity Studies 

November 17th, 2025 1 minute read

A sponsor needed to pool data from four MS spasticity studies—one still ongoing with another vendor—while adapting mi...

IDAC for a Phase III Study in Thrombotic Microangiopathy: Delivering High-Quality Statistical Support Within Budget Constraints

IDAC for a Phase III Study in Thrombotic Microangiopathy: Delivering High-Quality Statistical Support Within Budget Constraints

November 12th, 2025 1 minute read

Phastar acted as the Independent Data Analysis Centre (IDAC) for a Phase III trial in thrombotic microangiopathy (TMA...